Viridian Therapeutics Inc... (VRDN)
NASDAQ: VRDN
· Real-Time Price · USD
15.93
0.05 (0.31%)
At close: Jun 16, 2025, 3:59 PM
15.63
-1.88%
After-hours: Jun 16, 2025, 05:20 PM EDT
0.31% (1D)
| Bid | 15.05 |
| Market Cap | 1.3B |
| Revenue (ttm) | 302K |
| Net Income (ttm) | -308.32M |
| EPS (ttm) | -3.63 |
| PE Ratio (ttm) | -4.39 |
| Forward PE | -4.12 |
| Analyst | Buy |
| Ask | 16.38 |
| Volume | 602,264 |
| Avg. Volume (20D) | 876,939 |
| Open | 15.81 |
| Previous Close | 15.88 |
| Day's Range | 15.56 - 16.04 |
| 52-Week Range | 9.90 - 27.20 |
| Beta | 0.46 |
About VRDN
undefined
Industry n/a
Sector n/a
IPO Date n/a
Employees NaN
Stock Exchange n/a
Ticker Symbol VRDN
Website n/a
Analyst Forecast
According to 0 analyst ratings, the average rating for VRDN stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.
Stock Forecasts3 weeks ago
+7.8%
Viridian Therapeutics shares are trading higher af...
Unlock content with
Pro Subscription
6 months ago
+20.67%
Viridian Therapeutics shares are trading higher after the company announced Phase 3 results for its thyroid eye disease treatment trial.
2 weeks ago · businesswire.com
Viridian Therapeutics to Participate in Upcoming June Investor ConferencesWALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering, developing, and commercializing potential best-in-class medicines for s...
2 months ago · businesswire.com
Viridian Therapeutics Appoints Jeff Ajer to its Board of DirectorsWALTHAM, Mass.--(BUSINESS WIRE)--Viridian Therapeutics, Inc. (Nasdaq: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare di...